Crushed Ticagrelor Versus Eptifibatide Bolus + Clopidogrel
Completed · Phase 2
Conditions studied: Acute Coronary Syndrome, Angina, Unstable
In brief
Patients with troponin-negative acute coronary syndrome (ACS) are not routinely pre-treated with P2Y12 inhibitors and the rate of high on-treatment platelet reactivity (HPR) remains elevated after a loading dose of ticagrelor at the time of percutaneous coronary intervention (PCI). This suggests that faster platelet inhibition with crushed ticagrelor , eptifibatide , or cangrelor is needed to reduce HPR and periprocedural myocardial infarction and injury (PMI). The present study compared the effects of crushed ticagrelor vs. eptifibatide bolus + clopidogrel in troponin-negative ACS patients undergoing PCI.
Key facts
- Study ID
- NCT02925923
- Run by
- University of Alabama at Birmingham
- People needed
- 100
- Starts
- 2016-11-01
- Expected to finish
- 2018-12-01
- Last updated by the study team
- 2020-05-04
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Patients with unstable angina/troponin negative ACS.
You may not qualify if…
- need for oral anticoagulation therapy (Warfarin, Dabigatran, Rivaroxaban, Apixaban, Edoxaban)
- increased risk of bradycardia, and the associated therapy with a strong cytochrome P-450 inhibitors (anti-retroviral agents, antifungal agents and some antibiotics eg. Indinavir, Nelfinavir, Lopinavir, Ritonavir, Itraconazole, Ketoconazole, Voriconazole, Clarithromycin, Telithormycin)
- surgery<4 weeks
- use of any thienopyridines (Clopidogrel, Prasugrel) 7 days prior to randomization
- administration of GP IIb/IIIa inhibitors
- bleeding diathesis or major bleeding episode within 2 weeks
- thrombocytopenia (Platelet count < 100000)
- incessant chest pain
- hemodynamic instability (Mean arterial pressure < 65 mm Hg; need for vasopressor or inotropic agents; need for mechanical circulatory support for coronary intervention), NSTEMI as evidenced by elevation of troponin levels (Troponin > 0.034 ng/ml); renal failure with a serum creatinine >2.0 mg/dL
- anemia with HCT<30%.
Where it is running
- University of Alabama — Birmingham, Alabama, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.